Galectin-1 in Stable Liver Transplant Recipients
The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver...
Saved in:
| Published in | Transplantation proceedings Vol. 47; no. 1; pp. 93 - 96 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.01.2015
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients.
Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group.
The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group.
These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation. |
|---|---|
| AbstractList | The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the "Holy Grail" in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients.INTRODUCTIONThe achievement of a state of tolerance and minimization of the immunosuppressive load form part of the "Holy Grail" in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients.Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group.METHODSSerum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group.The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group.RESULTSThe concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group.These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation.CONCLUSIONSThese preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation. The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients. Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group. The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group. These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation. Abstract Introduction The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1 recently has been described to be involved in the maintenance of a tolerant environment, but there is no evidence of its role in human liver transplantation. The aim of our study was to measure the serum levels of galectin-1 in stable liver transplant recipients. Methods Serum levels of galectin-1 were determined in 30 stable liver transplant recipients who had been free of rejection episodes for at least 8 years. Fifteen patients with an acute rejection episode and 34 healthy subjects were used as the control group. Results The concentrations of galectin-1 were significantly higher in stable liver transplant recipients compared with healthy subjects and with the acute rejection group. Conclusions These preliminary results indicate that galectin-1 is upregulated in stable liver transplant recipients. Thus, our results extend the recent findings that galectin-1 may play an immune-suppressive role in liver transplantation. It remains to be established whether it might help to induce tolerance in liver transplantation. |
| Author | Iruzubieta, P. Crespo, J. Fábrega, E. López-Hoyos, M. Puente, Á. San Segundo, D. Llerena, S. Jurado, F. Arias, M. García, M.J. Casafont, F. |
| Author_xml | – sequence: 1 givenname: M.J. surname: García fullname: García, M.J. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 2 givenname: F. surname: Jurado fullname: Jurado, F. organization: Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain – sequence: 3 givenname: D. surname: San Segundo fullname: San Segundo, D. organization: Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain – sequence: 4 givenname: M. surname: López-Hoyos fullname: López-Hoyos, M. organization: Instituto de Investigación Márqués de Valdecilla (IDIVAL), Santander, Spain – sequence: 5 givenname: P. surname: Iruzubieta fullname: Iruzubieta, P. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 6 givenname: S. surname: Llerena fullname: Llerena, S. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 7 givenname: F. surname: Casafont fullname: Casafont, F. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 8 givenname: M. surname: Arias fullname: Arias, M. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 9 givenname: Á. surname: Puente fullname: Puente, Á. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 10 givenname: J. surname: Crespo fullname: Crespo, J. organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain – sequence: 11 givenname: E. surname: Fábrega fullname: Fábrega, E. email: digfge@humv.es organization: Gastroenterology and Hepatology Unit, University Hospital “Marqués de Valdecilla”, Santander, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25645780$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkd9LHDEQx0NR6mn7L8jiU192zSTZXz6UttZfcCBU-zxks7OQcy97TXKC_31znoIIwj2FwHc-M_OZQ7bnJkeMnQAvgEN1uiii1y6s_GSI-kJwUAWIgnP4xGbQ1DIXlZB7bMa5ghykKg_YYQgLnv5Cyc_sQJSVKuuGzxi_0iOZaF0OmXXZXdTdSNncPpLP7p-7jNrF7A8Zu7LkYvjC9gc9Bvr68h6xv5cX9-fX-fz26ub85zw3qlUxVx1VPXVNN9R1D1VXQtnWnKiVatBDaVJz1Qyy68q2FSSlJK10JVWvDPC-1fKIfdty05r_1hQiLm0wNKZxaFoHhKoUSjVSVil6_BJdd0vqceXtUvsnfN0yBX5sA8ZPIXga0Nioo51cEmlHBI4bsbjAt2JxIxZBYBKbEGfvEK9ddir-vS2mJOzRksdgkkxDvfVJPvaT3Q3z_R3GjNZZo8cHeqKwmNbepZMgYEgFeLc5_-b6oDiIRqoE-PUxYNcp_gOg5sY0 |
| CitedBy_id | crossref_primary_10_1016_j_jtct_2022_01_027 crossref_primary_10_1038_s41419_017_0220_3 crossref_primary_10_1007_s00262_020_02567_y crossref_primary_10_3389_ti_2023_11358 crossref_primary_10_1007_s10735_020_09898_1 crossref_primary_10_1007_s00408_021_00449_3 crossref_primary_10_1016_j_imlet_2018_01_009 |
| Cites_doi | 10.4049/jimmunol.176.10.6323 10.1002/lt.21724 10.1111/ajt.12088 10.1016/j.intimp.2010.03.001 10.1016/j.clim.2003.08.003 10.1016/0165-5728(90)90032-I 10.1038/ni.1772 10.1002/eji.201142325 10.1084/jem.190.3.385 |
| ContentType | Journal Article |
| Copyright | 2015 Elsevier Inc. Elsevier Inc. Copyright © 2015 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2015 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2015 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.transproceed.2014.12.001 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2623 |
| EndPage | 96 |
| ExternalDocumentID | 25645780 10_1016_j_transproceed_2014_12_001 S0041134514012834 1_s2_0_S0041134514012834 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W J5H K-O KOM L7B M41 MO0 N9A O-L O9- OAUVE OK- OW- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UDS WH7 X7M XPP Y6R Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c494t-4be6deb8bf77d16b515970ee934faf5c78048f3bb5992e333ea4a634d4c10d9a3 |
| IEDL.DBID | .~1 |
| ISSN | 0041-1345 1873-2623 |
| IngestDate | Mon Jul 21 11:08:24 EDT 2025 Thu Apr 03 07:02:40 EDT 2025 Tue Jul 01 02:02:28 EDT 2025 Thu Apr 24 22:59:55 EDT 2025 Fri Feb 23 02:18:32 EST 2024 Sun Feb 23 10:19:45 EST 2025 Tue Aug 26 18:32:50 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2015 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-4be6deb8bf77d16b515970ee934faf5c78048f3bb5992e333ea4a634d4c10d9a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 25645780 |
| PQID | 1652448336 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | proquest_miscellaneous_1652448336 pubmed_primary_25645780 crossref_citationtrail_10_1016_j_transproceed_2014_12_001 crossref_primary_10_1016_j_transproceed_2014_12_001 elsevier_sciencedirect_doi_10_1016_j_transproceed_2014_12_001 elsevier_clinicalkeyesjournals_1_s2_0_S0041134514012834 elsevier_clinicalkey_doi_10_1016_j_transproceed_2014_12_001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January-February 2015 2015 2015-01-00 2015 Jan-Feb 20150101 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – month: 01 year: 2015 text: January-February 2015 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Transplantation proceedings |
| PublicationTitleAlternate | Transplant Proc |
| PublicationYear | 2015 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Rabinovich, Daly, Dreja (bib3) 1999; 190 Xu, Tu, Xu (bib6) 2010; 10 Fábrega, López-Hoyos, San Segundo (bib8) 2009; 15 Offner, Colnik, Bringman (bib4) 1990; 28 Baum, Blackall, Arias-Magallano (bib5) 2003; 109 Moreau, Noble, Ratnasothy (bib9) 2012; 42 Toscano, Commodaro, llarregui (bib2) 2006; 176 Ye, Yan, Jiang (bib7) 2013; 13 Ilarregui, Croci, Bianco (bib1) 2009; 10 Ilarregui (10.1016/j.transproceed.2014.12.001_bib1) 2009; 10 Ye (10.1016/j.transproceed.2014.12.001_bib7) 2013; 13 Fábrega (10.1016/j.transproceed.2014.12.001_bib8) 2009; 15 Rabinovich (10.1016/j.transproceed.2014.12.001_bib3) 1999; 190 Baum (10.1016/j.transproceed.2014.12.001_bib5) 2003; 109 Moreau (10.1016/j.transproceed.2014.12.001_bib9) 2012; 42 Toscano (10.1016/j.transproceed.2014.12.001_bib2) 2006; 176 Xu (10.1016/j.transproceed.2014.12.001_bib6) 2010; 10 Offner (10.1016/j.transproceed.2014.12.001_bib4) 1990; 28 |
| References_xml | – volume: 190 start-page: 385 year: 1999 end-page: 398 ident: bib3 article-title: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T-cell apoptosis publication-title: J Exp Med – volume: 10 start-page: 981 year: 2009 end-page: 991 ident: bib1 article-title: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 publication-title: Nat Immunol – volume: 13 start-page: 569 year: 2013 end-page: 579 ident: bib7 article-title: Galectin-1 prolongs survival of mouse liver allografts from Flt3L-pretreated donors publication-title: Am J Transplant – volume: 42 start-page: 2881 year: 2012 end-page: 2888 ident: bib9 article-title: Absence of galectin-1 accelerates CD8+ T cell-mediated graft rejection publication-title: Eur J Immunol – volume: 176 start-page: 6323 year: 2006 end-page: 6332 ident: bib2 article-title: Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses publication-title: J Immunol – volume: 28 start-page: 177 year: 1990 end-page: 184 ident: bib4 article-title: Recombinant human beta-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis publication-title: J Neuroimmunol – volume: 10 start-page: 643 year: 2010 end-page: 647 ident: bib6 article-title: Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation publication-title: Int Immunopharmacol – volume: 15 start-page: 629 year: 2009 end-page: 633 ident: bib8 article-title: Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation publication-title: Liver Transpl – volume: 109 start-page: 295 year: 2003 end-page: 307 ident: bib5 article-title: Amelioration of graft vs host disease by galectin-1 publication-title: Clin Immunol – volume: 176 start-page: 6323 year: 2006 ident: 10.1016/j.transproceed.2014.12.001_bib2 article-title: Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses publication-title: J Immunol doi: 10.4049/jimmunol.176.10.6323 – volume: 15 start-page: 629 year: 2009 ident: 10.1016/j.transproceed.2014.12.001_bib8 article-title: Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation publication-title: Liver Transpl doi: 10.1002/lt.21724 – volume: 13 start-page: 569 year: 2013 ident: 10.1016/j.transproceed.2014.12.001_bib7 article-title: Galectin-1 prolongs survival of mouse liver allografts from Flt3L-pretreated donors publication-title: Am J Transplant doi: 10.1111/ajt.12088 – volume: 10 start-page: 643 year: 2010 ident: 10.1016/j.transproceed.2014.12.001_bib6 article-title: Immunological tolerance induced by galectin-1 in rat allogeneic renal transplantation publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2010.03.001 – volume: 109 start-page: 295 year: 2003 ident: 10.1016/j.transproceed.2014.12.001_bib5 article-title: Amelioration of graft vs host disease by galectin-1 publication-title: Clin Immunol doi: 10.1016/j.clim.2003.08.003 – volume: 28 start-page: 177 year: 1990 ident: 10.1016/j.transproceed.2014.12.001_bib4 article-title: Recombinant human beta-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis publication-title: J Neuroimmunol doi: 10.1016/0165-5728(90)90032-I – volume: 10 start-page: 981 year: 2009 ident: 10.1016/j.transproceed.2014.12.001_bib1 article-title: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 publication-title: Nat Immunol doi: 10.1038/ni.1772 – volume: 42 start-page: 2881 year: 2012 ident: 10.1016/j.transproceed.2014.12.001_bib9 article-title: Absence of galectin-1 accelerates CD8+ T cell-mediated graft rejection publication-title: Eur J Immunol doi: 10.1002/eji.201142325 – volume: 190 start-page: 385 year: 1999 ident: 10.1016/j.transproceed.2014.12.001_bib3 article-title: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T-cell apoptosis publication-title: J Exp Med doi: 10.1084/jem.190.3.385 |
| SSID | ssj0004243 |
| Score | 2.1068013 |
| Snippet | The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ transplantation. Galectin-1... Abstract Introduction The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the “Holy Grail” in solid organ... The achievement of a state of tolerance and minimization of the immunosuppressive load form part of the "Holy Grail" in solid organ transplantation. Galectin-1... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 93 |
| SubjectTerms | Adult Aged Biomarkers - blood Case-Control Studies Female Galectin 1 - blood Galectin 1 - immunology Graft Rejection - blood Graft Rejection - immunology Graft Rejection - prevention & control Humans Immune Tolerance Immunosuppressive Agents - therapeutic use Liver Transplantation Male Middle Aged Surgery Up-Regulation |
| Title | Galectin-1 in Stable Liver Transplant Recipients |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0041134514012834 https://www.clinicalkey.es/playcontent/1-s2.0-S0041134514012834 https://dx.doi.org/10.1016/j.transproceed.2014.12.001 https://www.ncbi.nlm.nih.gov/pubmed/25645780 https://www.proquest.com/docview/1652448336 |
| Volume | 47 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB9KRfBFtPXjrJYVpE-NzWYnmyziw1ms51fxoYW-LdlkA5EzPZrrw734tzuTZK-KFQ58S0KGDTuzOx_5zW8BXqk817ljKsSEq1VYIC0pNJTzUPacUv5gam5w_nqqZ-f46SK92ILj0AvDsMpx7x_29H63Hp8cjbN5tGga7vFFKRWmnCKQk2ROUMSMrfz1zxuYByYBOScjfjsQj_YYr2VPID54CoZ5YV8aHA-IucVJ_SsI7Z3RyQO4P0aRYjp86EPY8u0O7E5byqB_rMSB6HGdfcF8B-6-C1cH3wae6tWhOLtpu-oOe4E1g_VqF-IPBVfzmzaSomkFBaRu7sUXhnCIgQ19TgoRFHI2C-6n7B7B-cn7s-NZNB6tEJVocBmh87ryLnd1llVSO45qsth7o7Au6rRkWqK8Vs6lxiReKeULLLTCCksZV6ZQj2G7vWz9UxAGpdOuTGRdeMzjxJWV0i5xec3nkcblBEyYS1uOvON8_MXcBoDZd_u7HizrwcqE0XYTUGvZxcC-sZHUm6AyG_pLaUe05CQ2ks5uk_bduLg7K21Hb9q_DHACb9eSf9jwxiO_DPZlaZHzn5ui9ZfXNKJOKQzLldITeDIY3no-EuYDIn09-8_R9-Ae3aVDeek5bC-vrv0LCriWbr9fUftwZ_rx8-z0F8rDKgU |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NTgheEGwwyqeR0J4WLY4dNxbioUyMjnUVD520NytOHCmoZBXpHvrfc5fYHYghVeItSnJy5Pu-3P0M8F5kmcosQSEmVK2SuUSVkhpzHsyeU8wfdEUDzhczNbmUX6_Sqx04CbMw1FbpbX9v0ztr7e8c-908XtY1zfhKzoVMKUVAJynvwS6hU6UD2B2fnU9mt-ORSWie4xERBOzRrs1r1WGI986COr1kVx30Z8Tc4af-FYd2_uj0MTzygSQb99_6BHZcswf74waT6B9rdsi61s6uZr4H9z-Fq8NvPVT1-ojNbyev2qOOYANivd6H-EtOBf26iTirG4YxqV04NqUuDtYDoi-QJwyjznpJI5XtU7g8_Tw_mUT-dIWokFquImmdKp3NbDUalVxZCmxGsXNayCqv0oKQibJKWJtqnTghhMtlroQsZcHjUufiGQya68Y9B6Ylt8oWCa9yJ7M4sUUplE1sVtGRpHExBB320hQeepxOwFiY0GP23fzOB0N8MDyhhrshiA3tsgfg2IrqQ2CZCSOmaBQN-omtqEd3UbvW63druGnxTfOXDA7h44byDzHeeuV3Qb4M6jn9vMkbd32DK6oUI7FMCDWEg17wNvuRECQQ8uvFf67-Fh5M5hdTMz2bnb-Eh_gk7atNr2Cw-nnjXmP8tbJvvH79AuU2LLY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Galectin-1+in+Stable+Liver+Transplant+Recipients&rft.jtitle=Transplantation+proceedings&rft.au=Garc%C3%ADa%2C+M.J&rft.au=Jurado%2C+F&rft.au=San+Segundo%2C+D&rft.au=L%C3%B3pez-Hoyos%2C+M&rft.date=2015&rft.issn=0041-1345&rft.volume=47&rft.issue=1&rft.spage=93&rft.epage=96&rft_id=info:doi/10.1016%2Fj.transproceed.2014.12.001&rft.externalDBID=ECK1-s2.0-S0041134514012834&rft.externalDocID=1_s2_0_S0041134514012834 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00411345%2FS0041134515X00029%2Fcov150h.gif |